Dicycloverine, also known as dicyclomine, sold under the brand name Bentyl among others, is a medication that is used to treat spasms of the intestines such as those that occur in irritable bowel syndrome (IBS). It is taken by mouth or by injection into a muscle or vein. At the molecular level it is a tertiary amine antimuscarinic that competitively antagonizes muscarinic acetylcholine receptors on smooth muscle and secretory glands, producing decreased gastrointestinal smooth muscle tone and reduced cramping. It is formulated as oral capsules, tablets and liquid solutions and as a parenteral solution for intramuscular or intravenous administration. After oral dosing it is rapidly absorbed, undergoes hepatic metabolism and renal elimination, and has a relatively short elimination half life necessitating multiple daily doses for sustained effect. Clinically relevant cautions include anticholinergic adverse effects such as dry mouth, blurred vision, urinary retention and cognitive effects in older adults, and dose adjustments or avoidance in certain populations including those with severe ulcerative colitis, paralytic ileus, myasthenia gravis or narrow angle glaucoma.
Parent: Dicycloverine
Parent: Dicycloverine
Parent: Dicycloverine / Dicycloverine Hydrochloride
Typical quality control specifications for a dicycloverine active pharmaceutical ingredient define limits for individual and total impurities to ensure safety and stability. Common identified related compounds include N desmethyl dicycloverine, N oxide derivatives and hydroxylated or ring modified species; these identified related compounds are often controlled at or below 0.2 to 0.5 percent w by weight depending on the impurity and regulatory filing. Unspecified individual impurities are commonly limited to 0.3 to 0.5 percent w by weight and total impurities are typically limited to 1.0 to 2.0 percent w by weight in final API specifications. Residual solvents and elemental impurities are controlled to ICH guidelines with appropriate ppm level limits and validated analytical methods such as HPLC with mass confirmation or GC for volatile contaminants used to monitor the profile across stability and release testing.
Dicycloverine is used primarily as an antispasmodic for relief of intestinal cramping and pain associated with irritable bowel syndrome. It reduces smooth muscle spasm by blocking muscarinic receptors and is not an anti inflammatory or antibiotic agent.
Usual adult regimens prescribed by clinicians use multiple daily doses because of the short elimination half life, for example an oral dose every six hours is common. Exact dosing frequency and dose depend on formulation, patient age and comorbidities. Follow the prescribing information or a clinician’s directions and do not exceed recommended daily limits without medical supervision.
Dicyclomine is not primarily indicated to treat the cause of diarrhea. It may relieve cramp related pain that can accompany diarrheal illnesses, but it does not treat infectious causes and is not a first line therapy for diarrhea due to infection or toxin. Use under medical advice is recommended.
Dicycloverine is not indicated for gastroesophageal reflux disease and it is not considered a standard therapy for acid reflux. Anticholinergic effects can alter gastrointestinal motility and secretions and may not improve reflux symptoms; discuss options with a healthcare provider for treatments that target reflux specifically.
